川芎嗪注射液对冠心病心绞痛患者血脂相关指标的影响及其临床疗效分析

目的:探讨川芎嗪注射液治疗冠心病心绞痛的临床疗效。方法:选择2014年5月-2016年5月在我院接受治疗的冠心病心绞痛患者79例,根据治疗方法不同分为对照组(37例)和研究组(42例)。对照组患者给予常规治疗,研究组患者在对照组基础上给予川芎嗪注射液治疗。观察并比较两组患者的临床疗效。结果:治疗前,两组患者总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)及高密度脂蛋白胆固醇(HDL-C)水平比较,差异无统计学意义(P0.05);治疗后,两组患者总胆固醇(TC)、甘油三酯(TG)及低密度脂蛋白胆固醇(LDL-C)水平均显著降低,差异具有统计学意义(P0.05);治疗后,研究组患者总胆固醇(TC)、甘油三酯(TG)及低密度脂蛋白胆固醇(LDL-C)水平均低于对照组,差异具有统计学意义(P0.05);治疗后,两组患者高密度脂蛋白胆固醇(HDL-C)水平比较,差异无统计学意义(P0.05)。研究组患者治疗总有效率(92.86%)高于对照组(81.08%),差异具有统计学意义(P0.05)。结论:川芎嗪注射液治疗冠心病心绞痛的临床疗效显著,能够降低血脂相关指标水平,改善临床症状,值得临床推广应用。

Effects of Ligustrazine Injection on the SerumLevels of Patients with Coronary Heart Disease and Angina Pectoris

Objective:To investigate the influence of ligustrazine injection on the treatment of coronary heart disease (CHD) and angina pectoris.Methods:79 cases with angina pectoris who were treated in our hospital from May 2014 to May 2016 were selected and according to the different treatment methods, the patients were divided into the control group (37 cases) and the study group (42 cases). The patients in the control group were treated with conventional methods, while the patients in the study group were treated with ligustrazine injection on the basis of the control group. Then the clinical efficacy of two groups were observed and compared.Results:Before treatment, there was no statistically significant difference about the levels of the total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C) and high density lipoprotein cholesterol (HDL-C) between the two groups (P>0.05); After treatment, the levels of total cholesterol (TC), triglyceride (TG) and low density lipoprotein cholesterol (LDL-C) in the two groups were significantly lower than before, and the differences were statistically significant (P<0.05); After treatment, the levels of total cholesterol (TC), triglyceride (TG) and low density lipoprotein cholesterol (LDL-C) in the study group were lower than those of the control group, and the differences were statistically significant (P<0.05); After treatment, there was no statistically significant difference about the levels of the high density lipoprotein cholesterol (HDL-C) in the two groups (P>0.05); The total effective rate in the study group was 92.86%, which was higher than 81.08%in the control group, and the difference was statistically significant (P<0.05).Conclusion:Ligustrazine has obvious curative effect in treatment CHD and angina pectoris, which can improve the angina pectoris symptoms and be worthy of clinical application.